Close Menu

Almac

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Almac today said that it is teaming up with researchers at Queen's University, Belfast to develop pharmacogenomics tests for a variety of cancers.

Almac will run AclarusDx on the Affymetrix Dx2 platform. The test is based on Exonhit's proprietary biochip, a customized Affy GeneChip called the Genome Wide SpliceArray.

Paris-based Exonhit has already introduced AclarusDx to the French market and is planning to launch it in the wider European market.

Almac will analyze all samples performed with Exonhit's blood-based AclarusDx test.

Affymetrix, Almac Diagnostics, and Oxford Gene Technology are among the firms that have been awarded funding to develop new approaches for tumor profiling and data capture.

Almac researchers and academic collaborators used the company's Disease Specific Array platform to identify biomarkers associated with ovarian and breast cancer.

Almac, headquartered in Craigavon, Northern Ireland, said the new CLIA-registered lab supports its biomarker discovery and development strategy by "enabling the use of novel tests to stratify and enrich prospective clinical trials."

The firm said the lab will support its own needs as well as those of its pharmaceutical partners.

BioFocus has launched an FLT screening and profiling service using Almac's Flexyte assay platform and is offering services against targets such as proteases, phosphatases, and kinases.

Skyline Diagnostics' AMLprofiler leukemia test recently became the fourth Affy-based test to hit the market. Some of the company's other diagnostic partners, however, have changed their development strategies since the "Powered by Affymetrix" program was launched.

Pages

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.